Boviseal Dry Cow Intramammary Infusion

Valsts: Īrija

Valoda: angļu

Klimata pārmaiņas: HPRA (Health Products Regulatory Authority)

Aktīvā sastāvdaļa:

Bismuth subnitrate

Pieejams no:

Cross Vetpharm Group Limited

ATĶ kods:

QJ51X

SNN (starptautisko nepatentēto nosaukumu):

Bismuth subnitrate

Deva:

2.6 g/syringe

Zāļu forma:

Intramammary Infusion

Receptes veids:

LM: Licensed Merchant as defined in relevant national legislation

Ārstniecības grupa:

Cattle

Ārstniecības joma:

OTHER ANTIBACTERIALS FOR INTRAMAMMARY USE

Ārstēšanas norādes:

Miscellaneous

Autorizācija statuss:

Authorised

Autorizācija datums:

2003-06-30

Produkta apraksts

Health Products Regulatory Authority
08 January 2018
CRN000WLS
Page 1 of 5
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Boviseal Dry Cow Intramammary Infusion
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Active substance
Bismuth subnitrate 2.6g per 4g syringe
For a full list of excipients, see Section 6.1
3 PHARMACEUTICAL FORM
Intramammary infusion, dry cow.Grey to white coloured cream.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dairy cows at the end of lactation.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Boviseal is indicated for the prevention of new intramammary
infections throughout
the dry period. This results in a reduction in the incidence of
subclinical mastitis in
cows at calving, and of clinical mastitis in the dry period and the
subsequent
lactation (for at least 60 days after calving).
It is recommended that Boviseal be used as part of a herd approach to
dry cow
management and mastitis control. Cows considered likely to be free of
subclinical
mastitis should be given Boviseal at drying off according to the
criteria below. Other
animals should be managed in accordance with an approved mastitis
control plan or
specific veterinary advice.
For practical purposes, selection criteria may be based on the
mastitis and cell count
history of individual cows, or recognised tests for the detection of
subclinical mastitis
or bacteriological sampling. It is particularly important that, prior
to treatment, an
individual cell count be obtained from any cow with a history of
clinical mastitis
during the previous lactation. As a guide, cows with an average cell
count less than
200,000 cells/ml before drying off may be given Boviseal. A minor
increase (cell count
up to 250,000 cells/ml) during the last 4 weeks before drying off is
normal and may
be ignored. In case of doubt, veterinary advice should be sought.
Health Products Regulatory Authority
08 January 2018
CRN000WLS
Page 2 of 5
4.3 CONTRAINDICATIONS
Do not use in the lactating cow.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Details provided above apply.